There is some evidence that patients with Chronic Fatigue Syndrome
(CFS) suffer from immune abnormalities, such as immune activation and decreased immune cell responsivity upon polyclonal stimili. This study was designed to evaluate lymphocyte activation in CFS by using a CD69 expression assay. CD69 acts as a co-stimulatory molecule for T- and natural killer (NK) cell activation.
We collected whole blood from CFS patients, who met CDC criteria, and healthy volunteers. The blood samples were stimulated with mitogens during 18 h and the levels of activated T and NK cells expressing CD69 were measured on a Coulter Epics flow cytometer using a three color immunofluorescence staining protocol.
The expression of the CD69 activation marker on T cells (CD3+,
CD3+CD4+, and CD3+CD8+) and on NK cells (CD45+CD56+) was
significantly lower in CFS patients than in healthy subjects. These differences were significant to the extent that a significant diagnostic performance was obtained, i.e. the area under the ROC curve was around 89%. No differences either in the number of leukocytes or in the number or percentage of lymphocytes, i.e. CD3, CD4, CD8 and CD19, could be found between CFS patients and the controls. Patients with CFS show defects in T- and NK cell activation.
Since induction of CD69 surface expression is dependent on the activation of the protein kinase C (PKC) activation pathway, it is suggested that in CFS there is a disorder in the early activation of the immune system involving PKC.
Source: Neuro Endocrinology Letters. 2007 Jul 11;28(4) [E-publication ahead of print]. PMID: 17693977, Mihaylova I, Deruyter M, Rummens JL, Bosmans E, Maes M. MCare4U Outpatient Clinics, Belgium.